Citigroup’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.93M Buy
80,123
+69,087
+626% +$2.09M ﹤0.01% 2958
2026
Q1
$335K Buy
11,036
+8,177
+286% +$218K ﹤0.01% 3752
2025
Q4
$82.5K Sell
2,859
-4,061
-59% -$53K ﹤0.01% 4403
2025
Q3
$49.9K Sell
6,920
-22,608
-77% -$166K ﹤0.01% 4505
2025
Q2
$293K Sell
29,528
-64,676
-69% -$683K ﹤0.01% 3891
2025
Q1
$894K Buy
94,204
+295
+0.3% +$4.09K ﹤0.01% 3329
2024
Q4
$1.3M Buy
93,909
+73,456
+359% +$1.29M ﹤0.01% 3165
2024
Q3
$311K Buy
20,453
+9,190
+82% +$45.5K ﹤0.01% 4052
2024
Q2
$53.7K Sell
11,263
-67,089
-86% -$374K ﹤0.01% 4537
2024
Q1
$532K Buy
78,352
+54,554
+229% +$264K ﹤0.01% 3526
2023
Q4
$116K Sell
23,798
-37,793
-61% -$123K ﹤0.01% 4140
2023
Q3
$211K Buy
+61,591
New +$346K ﹤0.01% 3639
2022
Q2
Sell
-20
Closed 6262
2022
Q1
$0 Buy
+20
New +$79 ﹤0.01% 6325
2021
Q1
Sell
-900
Closed -$3K 6349
2020
Q4
$3K Sell
900
-200
-18% -$867 ﹤0.01% 7188
2020
Q3
$6K Hold
1,100
﹤0.01% 6885
2020
Q2
$5K Buy
+1,100
New +$4.79K ﹤0.01% 7257

Other funds holding CAPR

Citigroup's CAPR Position: Q2 2026 in Review

Citigroup increased its Capricor Therapeutics (CAPR) stake by 626% in Q2 2026, buying an estimated $2.09M and bringing the position to 80,123 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2958.

Citigroup first reported a position in CAPR in Q2 2020 and has held it in 16 quarters since. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Citigroup held 80,123 shares of Capricor Therapeutics worth $1.93M as of Q2 2026.
  • Citigroup bought 69,087 Capricor Therapeutics shares in Q2 2026, an estimated $2.09M.
  • Capricor Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2958 holding.
  • Citigroup first reported a position in Capricor Therapeutics in Q2 2020 and has held it in 16 quarters since.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.